Maybe not the best example... InterMune's ASCEND trial was tweaked slightly based on one successful and one failed Phase 3. I give the company a lot of credit too, I was a bit skeptical the "tweak" would do much and was a bit worried it may back fire but it would appear that ASCEND results are superior to even the successful CAPACITY-2.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.